Journal of psychopharmacology (Oxford, England)

Adding GLP-1 receptor drugs to reduce heart and metabolism risks in patients taking antipsychotics: A review of clinical trials

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Patients with schizophrenia spectrum or bipolar disorders may have reduced life expectancy due to cardiometabolic risk.

  • Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may impact cardiometabolic outcomes in these patients.
  • Evaluation of GLP-1 RAs could reveal potential benefits related to cardiometabolic health.
  • The meta-analysis aims to clarify the association between GLP-1 RAs and cardiometabolic risks.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Sep '25
Effect of lifestyle changes and GLP-1 drugs on weight and heart health markers in people with overweight or obesity
top 2% journal
cited by 25 papers
journal article
Jul '26
Effects and safety of GLP-1 drugs on heart and metabolism health in overweight or obese Chinese adults
top 50% journal
Nov '22
Folic acid supplements and malaria risk and severity in people using antifolate malaria drugs in affected areas
cited by 30 papers
systematic review
May '26
Medicines used to treat obesity in children and teenagers
systematic review
Jul '26
Effects of diabetes-related drugs on metabolism in schizophrenia patients taking antipsychotics
top 20% journal
Jan '26
Cotadutide’s effects on blood sugar control, weight loss, and safety in people with type 2 diabetes
cited by 2 papers
journal article
Jul '26
Effectiveness and safety of oral GLP-1 medicines for type 2 diabetes and obesity
top 10% journal
systematic review
Oct '25
Semaglutide treatment for adults with obesity
cited by 10 papers
systematic review
Sep '25
Effectiveness and Safety of GLP-1 Drugs in Children and Teens with Obesity or Type 2 Diabetes
top 1% journal
cited by 28 papers
systematic review
Sep '23
Weight loss from GLP-1 receptor drugs in non-diabetic people with overweight or obesity: A combined analysis of clinical trials
cited by 88 papers
systematic review

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
5 days ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
1 week ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
2 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
3 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
4 weeks ago7 studies
issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
5 weeks ago7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
6 weeks ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
7 weeks ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
8 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief